Brief: Basilea Pharmaceutica Launches Private Placement Of New Shares

Basilea Pharmaceutica AG, Allschwil

23/02/2021 16:50

Feb 23 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * LAUNCHES A PRIVATE PLACEMENT OF NEW SHARES BY WAY OF AN
ACCELERATED BOOKBUILDING
    * LAUNCH OF AN OFFERING OF UP TO 1 MILLION NEW REGISTERED
SHARES
WITH A PAR VALUE OF CHF 1.00 PER SHARE
    * NET PROCEEDS FROM THIS PRIVATE PLACEMENT WILL BE USED FOR
I)
CLINICAL DEVELOPMENT OF BASILEA'S CLINICAL ONCOLOGY DRUG
CANDIDATES DERAZANTINIB AND LISAVANBULIN
    * PRE-CLINICAL RESEARCH AND DEVELOPMENT ACTIVITIES
    * WORKING CAPITAL AND OTHER GENERAL CORPORATE PURPOSES,
INCLUDING
INVESTMENTS IN OR IN-LICENSING OF COMPLEMENTARY BUSINESSES,
PRODUCTS OR ASSETS
    * NEW SHARES CORRESPOND TO APPROXIMATELY 8% OF BASILEA'S
CURRENTLY
ISSUED SHARE CAPITAL
    * AND WILL BE ISSUED FROM COMPANY'S AUTHORIZED SHARE
CAPITAL,
EXCLUDING SUBSCRIPTION RIGHTS OF EXISTING SHAREHOLDERS
    * OFFER PRICE OF NEW SHARES WILL BE DETERMINED IN AN
ACCELERATED
BOOKBUILDING PROCESS, WHICH WILL START IMMEDIATELY
    * BOOKBUILDING PROCESS IS EXPECTED PRIOR TO MARKET OPEN ON
SIX
SWISS EXCHANGE ON FEBRUARY 24, 2021
    * NEW SHARES ARE EXPECTED TO BE LISTED AND ADMITTED TO
TRADING ON
SIX SWISS EXCHANGE ON FEBRUARY 26, 2021
    * NEW SHARES WILL RANK PARI PASSU WITH EXISTING SHARES
    * PAYMENT AND SETTLEMENT ARE EXPECTED TO TAKE PLACE ON OR
AROUND
FEBRUARY 26, 2021
    * BASILEA HAS AGREED TO A 150-DAY LOCK-UP PERIOD FOLLOWING
SETTLEMENT, SUBJECT TO CUSTOMARY EXCEPTIONS

Source text for Eikon:  ID:nGNE5DqQj3 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))